3.1 Board of Registration in Pharmacy: Structure & Enforcement

Board of Registration in Pharmacy: Structure & Enforcement

Massachusetts pharmacy practice is governed by three overlapping bodies of law, and the MPJE expects you to know which one answers which question:

• M.G.L. c. 112, §§ 24 through 42D — the pharmacy practice act (licensure, pharmacy permits, professional conduct, penalties).
• M.G.L. c. 94C — the Massachusetts Controlled Substances Act, administered jointly with the Department of Public Health (DPH) Drug Control Program.
• 247 CMR 2.00 through 21.00 — the Board's own promulgated regulations, made under the authority of c. 112 and c. 94C. Several widely cited chapters — 17.00 (sterile compounding), 18.00 (non-sterile compounding) and 22.00 (monetary penalties) — exist only as Board drafts and have not been promulgated; 247 CMR 9.19(1)(c) accordingly requires a pharmacy to keep the laws and regulations "247 CMR 2.00 through 21.00" on the premises.

A fourth source matters constantly in practice: 105 CMR 700.000 (implementation of c. 94C), 105 CMR 720.000 (the List of Interchangeable Drug Products) and 105 CMR 721.000 (prescription format and security) are DPH regulations, not Board regulations, and they are cited separately.

---

Board Composition — M.G.L. c. 13, § 22 (EXAM TRAP)

A very common wrong answer places the Board's membership in c. 112. It is not there. Every Massachusetts licensing board is constituted in M.G.L. Chapter 13; the Board of Registration in Pharmacy is created by M.G.L. c. 13, § 22. Chapter 112 tells you what the Board does; Chapter 13 tells you who is the Board.

The Governor appoints 13 members. Members serve three-year terms and may serve no more than two consecutive terms.

[!WARNING] Three traps in one table. (1) The number of years is 7 everywhere — there is no 5-year hospital seat. (2) A pharmacy technician sits on the Board; candidates routinely miss this because most states seat only pharmacists and lay members. (3) The thirteenth seat is a patient safety and quality improvement expert, a seat Massachusetts added after the 2012 New England Compounding Center meningitis outbreak.

The Board sits administratively within the Department of Public Health's Bureau of Health Professions Licensure.

---

What the Board Regulates: the 247 CMR Map

Knowing which chapter of 247 CMR answers a question is worth real points, because MPJE items are frequently written around a citation.

[!WARNING] Three chapters candidates cite as law are still drafts. 247 CMR 17.00 (sterile compounding), 247 CMR 18.00 (non-sterile compounding) and 247 CMR 22.00 (monetary penalties) are marked on their face as DRAFT (proposed new section) and are absent from the promulgated compilation, which stops at 21.00. The Board's own pharmacy application checklist still directs applicants to the draft 247 CMR 18.00. Until they are promulgated, sterile and non-sterile compounding are governed by M.G.L. c. 112, §§ 39F through 39J, the licensure requirements in 247 CMR 6.00, the duty in 247 CMR 9.01(3) to follow the most current USP chapters, and Board policy. Chapters 5.00 and 12.00 are reserved.

---

Inspection and Investigation

Board inspectors are pharmacists. They may enter and inspect a licensed pharmacy, and their scope reaches the premises, drug stock, prescription files, patient profiles, compounding and environmental-monitoring records, personnel training files and the pharmacy's electronic systems. A pharmacy that is cited receives an inspection report and must submit a plan of correction.

Two related duties follow from an inspection and are easy to forget:

• Under 247 CMR 20.03(6), a pharmacy must give the Board a copy of each inspection report, investigation report or FDA warning letter it receives from any local, state or federal agency within 14 calendar days of receipt.
• Under 247 CMR 20.03(5), a pharmacy must report any adverse change in accreditation status within 14 calendar days.

---

Adjudicatory Proceedings and Sanctions

Formal discipline proceeds under 247 CMR 10.00 and the Massachusetts Administrative Procedure Act, M.G.L. c. 30A. The Board issues an order to show cause; the licensee is entitled to counsel, to present and cross-examine witnesses, and to judicial review.

flowchart TD
    A[Complaint or inspection finding] --> B[Board investigation]
    B --> C{Board review}
    C -->|No violation| D[Dismissal or advisory letter]
    C -->|Settlement| E[Consent agreement]
    C -->|Immediate danger| F[Summary suspension]
    C -->|Formal track| G[Order to show cause, 247 CMR 10.00]
    G --> H[Adjudicatory hearing, M.G.L. c. 30A]
    F --> H
    H --> I[Final decision and sanctions]

Available sanctions include reprimand or censure, probation with practice conditions, suspension, revocation, voluntary surrender, and monetary penalties. Where a licensee poses an immediate threat to public health, safety or welfare, the Board may summarily suspend before a hearing, with an expedited post-suspension hearing to satisfy due process. A consent agreement resolves a matter without a full hearing and is a binding public final order.

Monetary Penalties — draft 247 CMR 22.00

The Board has drafted an explicit civil-penalty schedule at 247 CMR 22.00. Treat the figures as the Board's proposal rather than as promulgated law, because the chapter has not been adopted:

• Up to $25,000 per violation against a pharmacy for each violation of a statute, regulation or policy governing the practice of pharmacy.
• Up to $1,000 per day for each violation that remains uncorrected beyond the date prescribed for correction.
• A penalty is due 30 calendar days after issuance of the Assessment of Monetary Penalty notice if the licensee does not request a hearing.
• Failure to pay an assessed penalty is itself grounds for discipline.

The Board's underlying power to impose monetary penalties comes from M.G.L. c. 112, §§ 24A and 42D, which is what 247 CMR 22.00 would implement; that statutory authority is in force whatever the status of the draft chapter.

---

Fitness to Practise and the Inability to Practise Safely

The NABP blueprint treats "reporting to and participating in programs addressing the inability to practice with reasonable skill and safety" as a competency in its own right, alongside discipline. The two are related but distinct: discipline responds to conduct, while this limb responds to capacity — impairment through substance use disorder, physical illness or mental health condition.

The reporting side

Massachusetts builds the reporting duty into 247 CMR 20.03, and the deadlines are uniform:

Note what the first row does not say. The duty is triggered by the arrest or charge, not by a conviction, and not by an internal determination that the licensee is impaired. A licensee who waits for a case to resolve before telling the Board has already breached the regulation.

A licensee's own duty sits alongside the practical obligation of a Manager of Record to act on what he or she observes. The MOR is responsible for the operation of the pharmacy in compliance with the law and for the establishment, monitoring and enforcement of policies that maintain professional standards; a pharmacist who cannot practise safely cannot be left on the schedule while the MOR waits for a formal finding.

The participation side

The blueprint's second limb — participating in programmes addressing an inability to practise safely — refers to the monitoring and recovery arrangements that a board may accept in place of, or alongside, discipline. In outline, such an arrangement typically involves an assessment, a written agreement, a defined period of monitoring with testing and reporting, practice restrictions during monitoring, and the possibility of a return to unrestricted practice on successful completion. Where a licensee complies, boards commonly treat participation as an alternative to public discipline; where a licensee does not, the matter reverts to the formal disciplinary track.

[!IMPORTANT] Verify the current Massachusetts programme before relying on any description of it. The identity, sponsorship and terms of health-professional monitoring programmes change, and they are administered outside the Board's practice regulations. What is durable, and what the exam actually tests, is the structure: a self-reporting duty on a short fixed clock, a distinction between capacity and conduct, and a monitored alternative pathway that carries practice restrictions and reverts to discipline on non-compliance.

---

Advisories, Policies and Circular Letters

The Board publishes advisories, policies and circular letters interpreting its regulations — for example on extended absence of a Manager of Record, out-of-state Schedule II prescriptions, and pre-filled syringes. The DPH Drug Control Program issues circular letters (such as the Electronic Prescribing and Dispensing Manual, DCP 19-12-108). These do not carry the force of a promulgated regulation, but a licensee who departs from published Board guidance can expect that departure to be treated as evidence of substandard practice.